T he effectiveness of modern drugs like Ozempic and Mounjaro has helped revolutionize weight loss and the health issues that ...

MHRA launches genetic study into GLP-1 drug risks as Spain investigates Novo Nordisk for potential advertising violations.

Adults with type 2 diabetes and chronic kidney disease have a lower risk for adverse renal outcomes with semaglutide, ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

At least 10 people have now died following side-effects allegedly caused by GLP-1 weight loss jabs. Over a million people ...

Access is opening up for Kiwis to a weight loss drug described as a game changer. Wegovy, made by pharma-co Novo Nordisk, ...

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke ...

Biocon has scrapped its plans to introduce generic versions of Novo Nordisk's Ozempic and Wegovy in China, citing intense ...

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said.

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

With Novo Nordisk’s Wegovy already in the market, Eli Lilly is stepping up its game with a patient-friendly pen device, ...